PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia
Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.
Source: news-medical.net